Abstracts tagged "Patient reported outcomes"

Abstract Number: 1596 • ACR Convergence 2021
Changes in Patient-Reported Outcome (PRO) Scores During the COVID-19 Pandemic: Data from the ArthritisPower Research Registry
Kelly Gavigan¹, Esteban Rivera¹, Jeffrey Curtis², Shilpa Venkatachalam¹, Laura Stradford³, David Curtis¹ and William Nowell¹, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Nyack, NY
Background/Purpose: The COVID-19 pandemic caused particular concern among patients with autoimmune and rheumatic disease (ARD) due to increased risk of infection, and heightened sense of…
Abstract Number: 1871 • ACR Convergence 2021
Characterization of Symptoms of Nasal Disease in Relapsing Polychondritis Using Patient-Reported Data
Shubhasree Banerjee¹, Nancy Linn², nathalie costedoat-Chalumeau³, Guillaume Moulis⁴, Peter Merkel¹, Peter Grayson⁵ and Marcela Ferrada⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Relapsing Polychondritis Foundation Inc., New York, NY, ³Inserm DR Paris 5, Paris, France, ⁴Toulouse University Hopital, Toulouse, France, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁶National Institutes of Health, Bethesda, MD
Background/Purpose: Nasal chondritis is a well-recognized manifestation of relapsing polychondritis (RP), occasionally leading to saddle nose deformity. Early symptoms of nasal chondritis such as nose…
Abstract Number: 0314 • ACR Convergence 2021
PROMIS Provides a Broad Overview of Health-Related Quality of Life in the Evaluation of Sjogren’s Syndrome
Dana DiRenzo¹, Susan Robinson², Clifton Bingham¹, Alan Baer³ and Thomas Grader-Beck¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Sjogren’s Syndrome (SS) is a systemic autoimmune disease that has considerable impact on health-related quality of life (HRQL). The European League Against Rheumatism (EULAR)…
Abstract Number: 0630 • ACR Convergence 2021
Telemedicine in Rheumatology Care: A Systematic Review
Lesley Jackson¹, Timothy Edgil², Brittany Hill³, Catherine H. Smith⁴, Jasvinder Singh¹ and Maria I. Danila¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of General Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Brookwood Baptist Health, Leeds, AL, ⁴Lister Hill Library of the Health Sciences, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Coronavirus disease 2019 (COVID-19) pandemic led to a dramatic uptake of telemedicine in rheumatology. Given the impact of the pandemic on care delivery, we…
Abstract Number: 0753 • ACR Convergence 2021
Patient-Reported Burden of Adverse Drug Reactions Attributed to the Use of Adalimumab and Etanercept in Patients with Inflammatory Rheumatic Diseases
John Davelaar¹, Naomi Jessurun², Sander Tas³, Mike Nurmohamed⁴, Bart van den Bemt⁵ and Harald Vonkeman⁶, ¹Netherlands Pharmacovigilance Centre Lareb, Utrecht, Netherlands, ²Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, Netherlands, ³Amsterdam UMC, locatie AMC, Utrecht, Netherlands, ⁴Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁵Sint Maartenskliniek; Radboud University Medical Center, Ubbergen, Netherlands, ⁶Medisch Spectrum Twente; University of Twente, Enschede, Netherlands
Background/Purpose: Health care professionals tend to focus on adverse drug reactions (ADRs) with the highest clinical impact. Subsequently, ADRs with less obvious clinical impact but…
Abstract Number: 0824 • ACR Convergence 2021
Physicians’ Reasons for Prescribing Janus Kinase Inhibitors (JAKi) in Patients with Rheumatoid Arthritis, and Associated Alignment Between Physicians and Patients in a Real-world Clinical Setting
Peter C Taylor¹, Bruno Fautrel², Yves Piette³, Susana Romero-Yuste⁴, Jasper Broen⁵, Martin Welcker⁶, Elizabeth Holdsworth⁷, Monia Zignani⁸, Katrien Van Beneden⁸, Roberto Caporali⁹ and Rieke Alten¹⁰, ¹University of Oxford, Oxford, United Kingdom, ²Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ³AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium, ⁴Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ⁵Maxima Medical Centre, Veldhoven, Netherlands, ⁶MVZ für Rheumatologie, Planegg, Germany, ⁷Adelphi Real World, Bollington, United Kingdom, ⁸Galapagos, NV, Mechelen, Belgium, ⁹Policlinico S. Matteo University, Pavia, Italy, ¹⁰Schlosspark-Klinik University, Berlin, Germany
Background/Purpose: Shared decision making, a cornerstone of rheumatoid arthritis (RA) management1, allows physicians and their patients to make informed decisions about their treatment goals and…
Abstract Number: 1165 • ACR Convergence 2021
“What Matters”: Patient and Clinician Perspectives in Psoriatic Arthritis Care
Philip Mease¹, Dan Furst², Evan Siegel³, Vibeke Strand⁴, Melissa Mcilraith⁵, Elaine Husni⁶ and M. Cameron Hay⁷, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²University of California Los Angeles, Los Angeles, CA, ³Arthritis and Rheumatism Associates, Potomac, MD, ⁴Stanford University School of Medicine, Portola Valley, CA, ⁵M.Mc. Consulting, Dallas, TX, ⁶Cleveland Clinic, Cleveland, OH, ⁷Miami University (Ohio), Oxford, OH
Background/Purpose: Recent psoriatic arthritis (PsA) treatment recommendations (1), highlight the importance of shared decision making; this ideally requires the clinician understands “what matters” to each…
Abstract Number: 1293 • ACR Convergence 2021
Studying Clusters of Patients with SLE According to Cognitive Function, Self-reported Outcomes, Disease Activity, and Clusters Dynamic over 1 Year
Ambika Gupta¹, Sindhu Johnson², Jiandong Su³, Kathleen Bingham⁴, Andrea Knight⁵, Juan Diaz-Martinez⁶, Mahta Kakvan³, Maria Tartaglia³, Lesley Ruttan⁴, Joan Wither³, May Choi⁷, Marvin Fritzler⁸, Dennisse Bonilla³, Dorcas Beaton⁹, Patricia Katz¹⁰, Robin Green³ and Zahi Touma¹, ¹University of Toronto, Mississauga, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Toronto, ON, Canada, ⁵Hospital for Sick Children, Toronto, ON, Canada, ⁶UHN, Toronto, ON, Canada, ⁷Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Institute for Work & Health, Toronto, ON, Canada, ¹⁰University of California San Francisco, San Francisco, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) has a high prevalence of cognitive impairment (CI) (38% (95% confidence interval: 33-43%)). Patient reported outcomes (PROs) capture patient perceptions…
Abstract Number: 1598 • ACR Convergence 2021
Trends in Medication Interruptions and Associations with Disease Flares During a Public Health Crisis: Longitudinal Data from Patients with Autoimmune Rheumatic Diseases During the COVID-19 Pandemic
Tiffany Dharia¹, Michael George², SHILPA VENKATACHALAM³, Shubhasree Banerjee², Joshua Baker², David Curtis⁴, Maria I. Danila⁵, Kelly Gavigan⁴, Peter Merkel², Dianne Shaw⁶, Jeffrey Curtis⁷ and William Nowell⁴, ¹Hospital of the University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Vasculitis Foundation, Kansas City, MO, ⁷Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The COVID-19 pandemic has had substantial impact on the care of patients with autoimmune rheumatic diseases (ARDs), resulting in frequent medication interruptions early in…
Abstract Number: 1894 • ACR Convergence 2021
Natural Language Processing Tool for Extraction of Patient-Reported Outcomes from a National Multi-Electronic Health Records Registry
Marie Humbert-Droz¹, Zara Izadi², Gabriela Schmajuk², Milena Gianfrancesco², Jinoos Yazdany² and Suzanne Tamang³, ¹Stanford University, Stanford, ²University of California San Francisco, San Francisco, CA, ³Stanford Center for Population Health Sciences, Redwood City, CA
Background/Purpose: Patient reported outcomes (PROs) are increasingly used to track disease activity and facilitate shared decision making in patients with RA. Assessments of disease activity…
Abstract Number: 0359 • ACR Convergence 2021
Patient Journey with Axial Spondyloarthritis: Critical Issues from the Patient Perspective. Results from the European Map of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Denis Poddubnyy², Christine Bundy³, Laura Christen⁴, Raj Mahapatra⁵, Souzi Makri⁶, Carlos Jesús Delgado-Domínguez⁷, Sergio Sanz-Gomez⁷, Pedro Plazuelo-Ramos⁸ and Victoria Navarro-Compán⁹, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁶Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁸Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁹Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain
Background/Purpose: The journey of axial spondyloarthritis (axSpA) for most patients is slow and arduous. The goal of this analysis is to assess the journey to…
Abstract Number: 0664 • ACR Convergence 2021
Which Attributes Are the Most and Least Important to Patients When Considering Gout Flare Burden over Time? A Best-worst Scaling Choice Study
Jeremy Holyer¹, William Taylor², Angelo Gaffo³, Graham Hosie¹, Anne Horne¹, Borislav Mihov¹, Isabel Su¹, Gregory Gamble¹, Nicola Dalbeth¹ and Sarah Stewart¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago Wellington, Auckland, New Zealand, ³University of Alabama at Birmingham Medical Centre, Birmingham, AL
Background/Purpose: Several factors contribute to the patient experience of gout flares, including pain intensity, duration, frequency, and disability. It is unknown which of these factors…
Abstract Number: 0754 • ACR Convergence 2021
Bridging the Gap Between Patient-Reported Outcomes and Disease-Related Outcomes in Lupus – a Feasibility Study
Shivani Garg¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Patients with SLE have significantly worse health-related quality of life (QOL) at an earlier age compared to patients with other chronic diseases. This highlights…
Abstract Number: 0827 • ACR Convergence 2021
Discontinuation Rate of Tofacitinib as Monotherapy Is Similar Compared to Combination Therapy with Methotrexate in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada
Mohammad Movahedi¹, Denis Choquette², Louis Coupal², Angela Cesta³, Xiuying Li³, Edward Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ³Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ⁴Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). We previously…
Abstract Number: 1167 • ACR Convergence 2021
Rheumatoid Arthritis Patients’ Treatment Goals Relate to Disease Activity and Rheumatology Experiences
Kelly O'Neill¹, Pamela Sinicrope², Kathryne Marks³, Elena Myasoedova², Cynthia Crowson⁴ and John Davis², ¹Rheumatoid Patient Foundation, Lutz, FL, ²Mayo Clinic, Rochester, MN, ³Rheumatoid Patient Foundation, Boston, MA, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: Shared decision making and treat to target are recognized guidelines to treat Rheumatoid Arthritis (RA). We previously reported associations of shared treatment goal discussions…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].